Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atipamezole SCHEMBL3526769 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1BKMT2A | |
| Atipamezole SCHEMBL31147780 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1BKMT2A | |
| SCHEMBL9325632 | 0.88 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9325667 | 0.84 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9325681 | 0.83 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1B | |
| Fipamezole SCHEMBL1271449 | 0.83 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1BAXL | |
| SCHEMBL7642900 | 0.83 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL8610304 | 0.83 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| Fipamezole SCHEMBL935549 | 0.83 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1BAXL | |
| Hydrochloric Acid SCHEMBL9325923 | 0.83 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3220942-B1 | COMPOSITIONS COMPRISING LOW DOSE DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-04-27 | — | — | EP | claimed |
| WO-2026042013-A1 | MITOCHONDRIAL THERAPY | INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL (IOB) (CH) | 2026-02-26 | — | — | WO | disclosed |
| US-20250381167-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2025-12-18 | — | — | US | disclosed |
| EP-4662317-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF VENOUS THROMBOEMBOLISM | Universitetet i Tromsø - Norges Arktiske Universitet (NO) | 2025-12-17 | — | — | EP | disclosed |
| EP-4658639-A1 | N,N-DIALKYL-4-(2-ETHYLINDAN-2-YL)-1H-IMIDAZOLE-1-CARBOXAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Univerza V Ljubljani (SI) | 2025-12-10 | — | — | EP | disclosed |
| US-20250354986-A1 | AFFINITY ENCODED OSCILLATOR ARRAYS, METHODS, AND RELATED ASPECTS FOR MEASURING MOLECULAR BINDING KINETICS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250345433-A1 | Drug For Treating Disorders Of An Organ Or Tissue Function And Diseases Accompanied By Such Disorders, And The Method For Obtaining It | Epshtein, Oleg Iliich (RU) | 2025-11-13 | — | — | US | disclosed |
| US-20250333482-A1 | MODULATORS OF MESOTHELIAL ECM MOVEMENT | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2025-10-30 | — | — | US | disclosed |
| US-20250277021-A1 | Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists | REGENERON PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-0618906-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ANTII SAKARI HAAPALINNA (FI) | 1994-10-12 | — | — | EP | disclosed |
| EP-0589957-A1 | USE OF ATIPAMEZOLE FOR THE TREATMENT OF MALE SEXUAL IMPOTENCE. | ORION YHTYMAE OY (FI) | 1994-04-06 | — | — | EP | disclosed |
| EP-0372954-B1 | Substituted imidazole derivatives and their preparation and use | ORION YHTYMAE OY (FI) | 1994-03-09 | — | — | EP | disclosed |
| US-5292887-A | Antgonists at postsynoptic adrenoreceptors; hypotensive and antidiabetic agents | FARMOS-YHTYMA OY (FI) | 1994-03-08 | — | — | US | disclosed |
| CN-1023219-C | Substituted imidazole derivatives and their preparation and use | FARMOS OY (FI) | 1993-12-22 | — | — | CN | disclosed |
| WO-1993013074-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Orion-Yhtymä Oy (FI) | 1993-07-08 | — | — | WO | disclosed |
| WO-1992022296-A1 | USE OF ATIPAMEZOLE FOR THE TREATMENT OF MALE SEXUAL IMPOTENCE | Orion-Yhtymä Oy (FI) | 1992-12-23 | — | — | WO | disclosed |
| WO-1991018886-A1 | COMPOUNDS FOR THE TREATMENT OF AGE-RELATED MEMORY IMPAIRMENT AND OTHER COGNITIVE DISORDERS | Orion-Yhtymä Oy (FI) | 1991-12-12 | — | — | WO | disclosed |
| CN-1043128-A | The imdazole derivatives and the preparation thereof that replace | FARMOS OY (FI) | 1990-06-20 | — | — | CN | disclosed |
| EP-0372954-A1 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÀ OY (FI) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | ADRA2A 3352/4885ADRA2B 3146/4885ADRA2C 3948/4885 |
| US-20250381167-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | ADRA2A 1133/4885ADRA2B 856/4885ADRA2C 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.